What is the first line treatment for Mucormycosis?

The first line treatment for Mucormycosis is best represented by the combination of surgical debridement and intravenous amphotericin B. This approach is critical because Mucormycosis is a severe fungal infection often affecting immunocompromised individuals or those with underlying conditions such as diabetes.

Surgical debridement is essential in this treatment regimen as it helps to remove necrotic and infected tissue, which is fundamental to control the spread of the infection. Amphotericin B, particularly the lipid formulations, is the preferred antifungal agent due to its broad-spectrum activity against the molds responsible for Mucormycosis.

Other options listed do not align with the established treatment protocols for this aggressive infection. For instance, Itraconazole is a less effective agent for Mucormycosis compared to amphotericin B, and is not typically utilized in severe cases. Griseofulvin and fluconazole are not used for Mucormycosis as they are more effective against dermatophyte infections and certain yeasts, respectively. Topical antifungals may also not provide the necessary systemic coverage required for such an invasive disease, and relying on them along with surgical intervention is inadequate given the severity